Posted by Michael Wonder on 08 Feb 2024
Crovalimab approved in China as the first country for the treatment of paroxysmal nocturnal haemoglobinuria
8 February 2024 - Crovalimab, the fifth Chugai originated global drug, approved for the first time in the world.
Chugai Pharmaceutical today announced that crovalimab, a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai, was approved by the National Medical Products Administration of People’s Republic of China for treatment of adults and adolescents (12 years of age and above) with paroxysmal nocturnal haemoglobinuria not been previously treated with complement inhibitors.
